PL2411393T3 - Pochodne skondensowanego pirymidynodionu jako modulatory TRPA1 - Google Patents

Pochodne skondensowanego pirymidynodionu jako modulatory TRPA1

Info

Publication number
PL2411393T3
PL2411393T3 PL10755503T PL10755503T PL2411393T3 PL 2411393 T3 PL2411393 T3 PL 2411393T3 PL 10755503 T PL10755503 T PL 10755503T PL 10755503 T PL10755503 T PL 10755503T PL 2411393 T3 PL2411393 T3 PL 2411393T3
Authority
PL
Poland
Prior art keywords
dione derivatives
fused pyrimidine
trpa1 modulators
trpa1
modulators
Prior art date
Application number
PL10755503T
Other languages
English (en)
Inventor
Sachin Sundarlal Chaudhari
Sukeerthi Kumar
Abraham Thomas
Nisha Parag Patil
Ashok Bhausaheb Kadam
Vishal Govindrao Deshmukh
Sachin Vasantrao Dhone
Rajendra Prakash Chikhale
Neelima Khairatkar-Joshi
Indranil Mukhopadhyay
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of PL2411393T3 publication Critical patent/PL2411393T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL10755503T 2009-03-23 2010-03-17 Pochodne skondensowanego pirymidynodionu jako modulatory TRPA1 PL2411393T3 (pl)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
IN2212MU2009 2009-09-23
IN2211MU2009 2009-09-23
US25194409P 2009-10-15 2009-10-15
US25326309P 2009-10-20 2009-10-20
IN2891MU2009 2009-12-15
IN2892MU2009 2009-12-15
US29446310P 2010-01-12 2010-01-12
US30024110P 2010-02-01 2010-02-01
EP10755503.9A EP2411393B1 (en) 2009-03-23 2010-03-17 Fused pyrimidine-dione derivatives as trpa1 modulators
PCT/IB2010/000553 WO2010109287A1 (en) 2009-03-23 2010-03-17 Fused pyrimidine-dione derivatives as trpa1 modulators

Publications (1)

Publication Number Publication Date
PL2411393T3 true PL2411393T3 (pl) 2014-06-30

Family

ID=42780198

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10755503T PL2411393T3 (pl) 2009-03-23 2010-03-17 Pochodne skondensowanego pirymidynodionu jako modulatory TRPA1

Country Status (24)

Country Link
US (1) US9000159B2 (pl)
EP (2) EP2411393B1 (pl)
JP (1) JP5657638B2 (pl)
KR (1) KR20110132575A (pl)
CN (1) CN102361873B (pl)
AP (1) AP3280A (pl)
AU (1) AU2010227245B2 (pl)
BR (1) BRPI1013559A2 (pl)
CA (1) CA2756518A1 (pl)
CL (2) CL2011002315A1 (pl)
DK (1) DK2411393T3 (pl)
EA (1) EA023857B1 (pl)
ES (2) ES2456515T3 (pl)
HK (2) HK1166075A1 (pl)
IL (1) IL215178A (pl)
MX (1) MX2011009824A (pl)
PE (1) PE20120774A1 (pl)
PL (1) PL2411393T3 (pl)
PT (1) PT2411393E (pl)
SG (1) SG174402A1 (pl)
SI (1) SI2411393T1 (pl)
UA (1) UA108069C2 (pl)
WO (1) WO2010109287A1 (pl)
ZA (1) ZA201107648B (pl)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090054984A (ko) 2006-08-07 2009-06-01 아이언우드 파마슈티컬스, 인코포레이티드 인돌 화합물
CN102361873B (zh) 2009-03-23 2014-07-09 格兰马克药品股份有限公司 作为trpa1调节剂的稠合嘧啶二酮衍生物
AR084294A1 (es) 2010-12-20 2013-05-08 Glenmark Pharmaceuticals Sa Compuestos de 2-amino-4-ariltiazol, metodos para su sintesis y uso como antagonista de trpa1
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
JP2014517031A (ja) 2011-06-13 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニストを使用した呼吸器疾患の治療
JP2014517062A (ja) 2011-06-22 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． ＴＲＰＡ１アンタゴニスト及びβ２アゴニストを含む医薬組成物
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
JP2014521634A (ja) 2011-07-25 2014-08-28 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニスト及びステロイドを含む医薬組成物
MX2014001551A (es) 2011-08-09 2014-09-15 Hydra Biosciences Inc Inhibicion de canal ionico del potencial receptor transitorio a1 (trpa1).
EP2787991A1 (en) 2011-12-05 2014-10-15 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
CN104203236A (zh) 2012-01-17 2014-12-10 味之素株式会社 杂环酰胺衍生物和含有其的药物
CA2873570C (en) 2012-06-08 2016-11-01 Glenmark Pharmaceuticals S.A. Amides of 2-amino-4-arylthiazole compounds and their salts as trpa1 modulators
KR102164756B1 (ko) 2012-10-01 2020-10-14 오리온 코포레이션 N-프로프-2-이닐 카복스아미드 유도체 및 trpa1 길항제로서의 이의 용도
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
RU2016115093A (ru) 2013-10-15 2017-11-21 Гленмарк Фармасьютикалс С.А. Фармацевтическая композиция, содержащая антагонист trpa1 и анальгетический агент
DK3064498T3 (da) * 2013-10-30 2019-10-07 Shanghai hengrui pharmaceutical co ltd Pyrazolopyrimidin- eller pyrrolotriazon-derivater, fremgangsmåde til fremstilling af samme, og farmakologiske anvendelser deraf
CN103755705B (zh) * 2014-02-17 2017-02-15 上海佰特因医药科技有限公司 一种天然产物四甲基尿酸的全合成方法
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
CN105001170A (zh) * 2015-07-13 2015-10-28 佛山市赛维斯医药科技有限公司 末端腈基取代的三氮唑亚砜类化合物、其制备方法及其用途
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
KR20200035043A (ko) * 2017-07-28 2020-04-01 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피리미돈 헤테로아릴 유도체를 제조하기 위한 방법 및 피리미돈 헤테로아릴 유도체의 중간체
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
CN108558836A (zh) * 2018-05-14 2018-09-21 东南大学 一类具有双重作用机制的dpp-4抑制剂及其用途
WO2023096915A1 (en) * 2021-11-24 2023-06-01 Slap Pharmaceuticals Llc Multicyclic compounds
TW202342465A (zh) * 2022-02-03 2023-11-01 美商Ｄ Ｅ 蕭爾研究有限公司 作為trpa1抑制劑之n3經取代脲嘧啶化合物
WO2023178035A1 (en) * 2022-03-14 2023-09-21 Slap Pharmaceuticals Llc Multicyclic compounds
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656473B (zh) * 2022-04-27 2023-09-29 成都施贝康生物医药科技有限公司 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656472B (zh) * 2022-04-27 2023-07-04 成都施贝康生物医药科技有限公司 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (es) * 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
AU2003290066A1 (en) 2002-12-18 2004-07-09 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
EP1713815A4 (en) 2004-02-11 2009-03-11 Smithkline Beecham Corp PTH AGONISTS
US20070196866A1 (en) 2004-03-13 2007-08-23 Irm Llc Modulators of ion channel trpa1
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
JPWO2006083005A1 (ja) 2005-02-03 2008-06-26 武田薬品工業株式会社 縮合ピリミジン誘導体およびその用途
US20060291462A1 (en) * 2005-06-28 2006-12-28 Utstarcom, Inc. Method and apparatus using multiple application cards to comprise multiple logical network entities
CN101384261B (zh) * 2005-12-22 2011-12-07 海德拉生物科学公司 治疗疼痛的组合物
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
TW200836743A (en) 2007-01-29 2008-09-16 Xenon Pharmaceuticals Inc Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
US8163761B2 (en) * 2007-06-22 2012-04-24 Hydra Biosciences, Inc. Methods and compositions for treating disorders
WO2009158719A2 (en) * 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN102361873B (zh) 2009-03-23 2014-07-09 格兰马克药品股份有限公司 作为trpa1调节剂的稠合嘧啶二酮衍生物
ES2424340T3 (es) 2009-03-23 2013-10-01 Glenmark Pharmaceuticals S.A. Derivados de isotiazolo-pirimidindiona como moduladores de TRPA1
PE20120834A1 (es) 2009-03-23 2012-07-25 Glenmark Pharmaceuticals Sa Derivados de furopirimidindiona como moduladores de trpa1
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
WO2010146006A2 (de) 2009-06-18 2010-12-23 Basf Se Fungizide mischungen
EP2311844A1 (en) 2009-10-15 2011-04-20 Interquim, S.A. Silyl polymeric benzoic acid ester compounds, uses, and compositions thereof
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
IN2012DN02577A (pl) 2009-10-15 2015-08-28 Pfizer
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
CA2771928C (en) 2010-07-13 2013-08-06 Novartis Ag Oxazine derivatives and their use in the treatment of neurological disorders

Also Published As

Publication number Publication date
CL2014001447A1 (es) 2014-10-17
IL215178A0 (en) 2011-12-29
HK1166075A1 (en) 2012-10-19
AU2010227245A2 (en) 2011-10-27
ES2551085T3 (es) 2015-11-16
CN102361873B (zh) 2014-07-09
EP2708538B1 (en) 2015-08-12
EP2411393A1 (en) 2012-02-01
EP2411393B1 (en) 2014-01-22
SI2411393T1 (sl) 2014-03-31
BRPI1013559A2 (pt) 2016-04-12
JP2012521401A (ja) 2012-09-13
HK1194742A1 (en) 2014-10-24
CN102361873A (zh) 2012-02-22
JP5657638B2 (ja) 2015-01-21
ES2456515T3 (es) 2014-04-22
AU2010227245A1 (en) 2011-09-22
ZA201107648B (en) 2012-07-25
EP2411393A4 (en) 2012-08-01
CA2756518A1 (en) 2010-09-30
UA108069C2 (uk) 2015-03-25
WO2010109287A1 (en) 2010-09-30
EA201190143A1 (ru) 2012-04-30
EP2708538A1 (en) 2014-03-19
AU2010227245B2 (en) 2015-09-10
KR20110132575A (ko) 2011-12-08
MX2011009824A (es) 2012-01-25
SG174402A1 (en) 2011-10-28
US20140128603A1 (en) 2014-05-08
PT2411393E (pt) 2014-02-21
US9000159B2 (en) 2015-04-07
AP3280A (en) 2015-05-31
DK2411393T3 (da) 2014-04-07
EA023857B1 (ru) 2016-07-29
AP2011005887A0 (en) 2011-10-31
IL215178A (en) 2015-01-29
PE20120774A1 (es) 2012-06-27
CL2011002315A1 (es) 2012-04-09

Similar Documents

Publication Publication Date Title
AP3280A (en) Fused pyrimidine-dione derivatives as TRPA1 modulators
AP2948A (en) Thienopyrmidinedione derivatives as TRPA1 modulators
HK1166081A1 (en) Isothiazolo-pyrimidinedione derivatives as trpa1 modulators
GB0912778D0 (en) Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) Fused aminodihydropyrimidone derivatives
ZA201008347B (en) Fused pyrimidineone compounds as trpv3 modulators
IL211933A0 (en) Novel fused aminodihydrothiazine derivative
EP2634188A4 (en) FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
EP2393359A4 (en) COMPOUND DIBENZIMIDAZOLE DERIVATIVES
HK1165423A1 (en) Fused pyrimidines
IL215119A0 (en) Substitted fused pyrimidine compounds
HK1201836A1 (en) Novel pyrrole derivatives
HK1179956A1 (zh) 作為 調節劑的稠合雜環衍生物
EP2229388A4 (en) CONDENSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS
GB0921967D0 (en) Novel Aryloxyanilide Derivatives
HK1173134A1 (en) Substituted halophenoxybenzamide derivatives
AP2011005883A0 (en) Furopyrimidinedione derivatives as TRPA1 modulators.
ZA201106695B (en) Substituted fused pyrimidine compounds